REGIONAL VARIATIONS ACROSS THE UNITED STATES IN THE PREVALENCE OF OVERT HEPATIC ENCEPHALOPATHY AND RIFAXIMIN UTILIZATION AMONG COMMERCIALLY AND MEDICARE INSURED ADULTS

被引：0

作者：

Wong, Robert J. ^{[1
,2
]}

Dashputre, Ankur A. ^{[3
]}

Gagnon-Sanschagrin, Patrick ^{[4
]}

Heimanson, Zeev ^{[5
]}

Maitland, Jessica

Bellefleur, Remi ^{[4
]}

Guerin, Annie ^{[4
]}

Sikes, Martha ^{[3
]}

Bumpass, Brock ^{[3
]}

Olujohungbe, Olamide ^{[3
]}

Borroto, Danellys ^{[3
]}

Joseph, George J. ^{[3
]}

机构：

[1] VA Palo Alto Healthcare Syst, Palo Alto, CA USA

[2] Stanford Univ Sch Med, Stanford, CA USA

[3] Bausch Hlth, Laval, PQ, Canada

[4] Anal Grp Inc, Denver, CO USA

[5] Salix Pharmaceut, Bridgewater, NJ USA

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

3100-A

引用

页码：S1408 / S1409

页数：2

共 50 条

[1] HEALTHCARE COST AND UTILIZATION OF HEPATIC ENCEPHALOPATHY: ANALYSIS OF COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES
Elsaid, Mohamed I.
Li, You
John, Tina
Pentakota, Ram
Rustgi, Vinod K.
HEPATOLOGY, 2019, 70 : 261A - 261A
[2] Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States
Volk, Michael L.
Burne, Rebecca
Guerin, Annie
Shi, Sherry
Joseph, George J.
Heimanson, Zeev
Ahmad, Maliha
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 202 - 211
[3] BURDEN OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS IN A COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES
Rice, J. Bradford
White, Alan
Johnson, Michaels
Simes, Mark
Zuckerman, Peter
Berman, Richard
Hovland, Sara
Huang, Xingyue
HEPATOLOGY, 2020, 72 : 1059 - 1059
[4] Impact of Rifaximin Use on Overt Hepatic Encephalopathy (OHE) Rehospitalizations Post-Discharge From an OHE Hospitalization in Commercially and Medicare-Insured Patients
Jesudian, Arun B.
Gagnon-Sanschagrin, Patrick
Bungay, Rebecca
Easson, Kaitlyn
Shah, Aditi
Guerin, Annie
Samson, Aaron
Olujohungbe, Olamide
Bumpass, Brock
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1240 - S1241
[5] THE PREVALENCE OF CIRRHOSIS IN THE UNITED STATES AMONG COMMERCIALLY INSURED ADULTS 2011-2018
Mazumder, Nikhilesh
Stephen, John
Kang, Raymond
Aikman, Cassandra
Parker, Emily D.
VanWagner, Lisa B.
Ladner, Daniela P.
HEPATOLOGY, 2020, 72 : 414A - 414A
[6] Cost and resource utilization associated with glioblastoma among commercially insured adults in the United States (US).
Jiang, Shan
Hill, Kala
Patel, Dipen
Waldeck, Adrian Reg
Botteman, Marc
Norden, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States
Rice, J. Bradford
White, Alan G.
Galebach, Philip
Korenblat, Kevin M.
Wagh, Aneesha
Lovelace, Belinda
Wan, George J.
Jamil, Khurram
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (08) : 1473 - 1480
[8] LONG TERM CARE SERVICES USE AMONG MEDICARE PATIENTS TREATED WITH RIFAXIMIN FOR OVERT HEPATIC ENCEPHALOPATHY
Gagnon-Sanschagrin, Patrick
Heimanson, Zeev
Allen, Christopher
Maitland, Jessica
Davidson, Mikhail
Zhang, Adina
Chen, Jingyi
Guerin, Annie
Dashputre, Ankur A.
Bumpass, Brock
Olujohungbe, Olamide
Borroto, Danellys
Joseph, George
GASTROENTEROLOGY, 2023, 164 (06) : S1400 - S1400
[9] Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
Mohamed I. Elsaid
You Li
Carolyn Catalano
Carlos D. Minacapelli
Kapil Gupta
Vinod K. Rustgi
PharmacoEconomics - Open, 2021, 5 : 89 - 100
[10] Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
Elsaid, Mohamed I.
Li, You
Catalano, Carolyn
Minacapelli, Carlos D.
Gupta, Kapil
Rustgi, Vinod K.
PHARMACOECONOMICS-OPEN, 2021, 5 (01) : 89 - 100

← 1 2 3 4 5 →